- Tumors1000+
- Pathologic Processes821
- Cancer749
- Pathology722
- Nervous System Diseases699
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes821
- Cancer749
- Pathology722
- Nervous System Diseases699
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PR positive
- PD-L1 negative
- EGFR negative
- EGFR positive
- ALK negative
- ER negative
- PR negative
- KRAS positive
- BRAF positive
- BRCA1 positive
- CD20 positive
- BRCA2 positive
- p16 positive
- ALK positive
- BRAF negative
- ROS1 negative
- MET positive
- MYC positive
- PIK3CA positive
- p16 negative
- HLA positive
- HR positive
- IDH positive
- RET positive
- CD5 positive
- ROS1 positive
- BCL2 positive
- CD19 positive
- HLA-A positive
- IDH negative
- MET negative
- dMMR positive
- BCL6 positive
- BCR-ABL1 positive
- MSI-H positive
- NRAS positive
- PALB2 positive
- TP53 negative
- TP53 positive
- BRCA positive
- Ex19del positive
- HBsAg positive
- HPV negative
- HPV positive
- L858R positive
- MSS positive
- RET negative
- BRCA1 negative
- CCND1 positive
- HLA negative
- HLA-A negative
- KRAS negative
- NF1 positive
- TTR positive
- anti-dsDNA positive
- ABCA4 positive
- ANA positive
- BRCA2 negative
- CD19 negative
- CD20 negative
- CD4 positive
- CFTR positive
- CLDN18.2 positive
- FGFR2 positive
- MDM2 positive
- MMR negative
- MMR positive
- MSI-H negative
- NTRK negative
- NTRK positive
- PTEN positive
- Philadelphia chromosome negative
- RAS positive
- RB1 negative
- RB1 positive
- T790M positive
- TROP2 negative
- TROP2 positive
- ctDNA positive
- dMMR negative
- 1p negative
- APP positive
- C5 positive
- CD23 positive
- COL7A1 positive
- EBV positive
- FLT3 negative
- FLT3 positive
- FMR1 positive
- HRAS positive
- MGMT negative
- MLH1 positive
- MSH2 positive
- MSH6 positive
- NF2 positive
- NRAS negative
- PMS2 positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia Chromosome positive
- RAS negative
- RF positive
- RHO positive
- p53 positive
- pMMR positive
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- AKT negative
- ALPL positive
- ATM positive
- Aβ1-42 positive
- BRCA negative
- CD1a positive
- CD2 positive
- CD22 negative
- CD3 positive
- CD34 positive
- CD7 positive
- CD8 positive
- CD99 positive
- CDK4 positive
- CEACAM5 positive
- COL1A1 positive
- COL1A2 positive
- DLL3 positive
- DMD positive
- Del(17p) negative
- ER or PR positive
- ER/PR positive
- EpCAM positive
- FGFR3 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GRN positive
- HBB positive
- HBV DNA negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HRD positive
- HTT positive
- HbE positive
- HbSS positive
- IGHV negative
- IGHV positive
- JAK2 positive
- KIT positive
- Ki-67 positive
- L861Q positive
- MGMT positive
- MSI negative
- MSS negative
- MYC negative
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PTCH1 positive
- PTEN negative
- PiZZ positive
- RAF positive
- S768I positive
- SMN1 positive
- SPINK5 positive
- TTR negative
- TdT positive
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- anti-Smith positive
- core antibody positive
- hepatitis B DNA negative
- kappa light chain positive
- lambda light chain positive
- myeloperoxidase negative
- other sickle cell syndrome variants positive
- surface antigen positive
- t(11;14) negative
- (null)(null) positive
- 11q del negative
- 11q del positive
- 11q23 abnormalities positive
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Anthracycline
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
4641 trials
Joliet, IL (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to see if using ADT intermittently can improve survival rate & reduce hot flashes in men with mCSPC, with PSA levels <0.2 ng/mL after 6 months of treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Joliet, IL (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will study the long-term effects of a treatment for neovascular age-related macular degeneration.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Recruiting
Unphased
0 Criteria Met
Eligibility Criteria
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different chemotherapy combinations to treat triple negative breast cancer to see which is more effective.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a combination of two drugs, XL092 and atezolizumab, against another treatment in patients with a specific type of colorectal cancer that has spread and not responded to standard treatments. The goal is to see if the new combination can better stop cancer growth and help the immune system fight the cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different experimental treatments for small cell lung cancer that has returned after one other treatment. One experimental treatment is a single drug, and the other experimental treatment is a combination of two drugs. The trial will compare how well the experimental treatments work to a standard treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the addition of the immunotherapy drug pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Hodgkin's Lymphoma trials are postedWe'll send you an email whenever new trials are posted
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether adding immunotherapy drugs to chemotherapy can better treat patients with newly diagnosed stage III or IV Hodgkin lymphoma.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new combination treatment for patients with untreated renal cell carcinoma. The usual treatment is immunotherapy with ipilimumab and nivolumab, followed by nivolumab alone. The new treatment adds cabozantinib to nivolumab after initial treatment with ipilimumab and nivolumab. It is not yet known if this new combination treatment is better than the usual treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing how well two cancer-fighting drugs work together, and whether adding a third drug makes them more effective in treating patients with advanced biliary tract cancers. The drugs aim to kill cancer cells, stop them from dividing, or prevent them from spreading.
Efficacy & Safety Awards
Approved for 10 Other Conditions
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic).
Efficacy & Safety Awards
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
SummaryThis trial is testing whether milvexian can help prevent another stroke in people who have already had one by stopping blood clots from forming. Milvexian may reduce the risk of stroke without significant bleeding.
Efficacy & Safety Awards
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying the effects of ranibizumab given through the Port Delivery System in people with diabetic retinopathy without center-involved diabetic macular edema.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
Get notified when new Chronic Lymphocytic Leukemia trials are postedWe'll send you an email whenever new trials are posted
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares acalabrutinib with rituximab combined with either idelalisib or bendamustine in patients with chronic lymphocytic leukemia who have already been treated before. Acalabrutinib stops cancer cells from growing, while rituximab helps the immune system kill them. Idelalisib blocks growth signals, and bendamustine damages cancer cell DNA. Acalabrutinib has been approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia in the US.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Joliet, IL (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
1
2
3
…50